NCT04266249 2026-03-02
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
Clinical Trials
8 trialsNCT03179904 2026-02-24
TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer
Mayo Clinic
Phase 2 Active not recruiting
NCT07407920 2026-02-12
Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02654119 2025-12-12
Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery
University of Nebraska
Phase 2 Completed
NCT04425018 2025-11-18
MARGOT
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT04329065 2025-11-06
Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer
University of Washington
Phase 2 Recruiting
NCT04680442 2025-04-06
SCHOLAR-2
Population Health Research Institute
Phase 2 Recruiting
NCT04197687 2023-12-18
TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery
Academic and Community Cancer Research United
Phase 2 Unknown